Labiana Health

Labiana Health Net Debt/Equity

The Net Debt to Equity Ratio of Labiana Health (LAB.MC) as of Nov 19, 2026 is 5.86. In the previous year, Net Debt to Equity Ratio was 9.37 — a change of -37.44% (lower).

Net Debt/Equity

5.86

YoY

-37.44%

Last updated:

Net Debt to Equity Ratio of Labiana Health is 2025 5.86 . Net Debt to Equity Ratio of Labiana Health was 2024 9.37 . It decreases by -37.44% lower compared to the previous year.

The Labiana Health Net Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/Equity
Date
Net Debt/Equity
Jan 1, 2018
0.92 EUR
Jan 1, 2019
2.07 EUR
Jan 1, 2021
2.03 EUR
Jan 1, 2022
1.52 EUR
Jan 1, 2023
8.29 EUR
Jan 1, 2024
9.37 EUR
Jan 1, 2025
5.86 EUR
The Labiana Health Net Debt/Equity history
YEARNet Debt/EquityYoY
5.86-37.44%
9.37+13.11%
8.29+445.86%
1.52-25.13%
2.03-2.07%
2.07+126.07%
0.92—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Labiana Health Stock analysis

What does Labiana Health do? Labiana Health SA generates revenue through the development, manufacturing, and marketing of animal and human medicines. The company focuses on drug research and development, including galenic and analytical development, as well as drug manufacturing, which encompasses formulation development and bacterial vaccine manufacturing. Regulatory services for pharmaceutical product registration in global markets also contribute to its income. Its subsidiaries operate in Ecuador, Mexico, Serbia, and Turkey, serving markets for both animal and human pharmaceutical products. The company's primary products include sterile and lyophilized dosage forms, which are manufactured for use in animal and human medicine. These products are sold to customers in the pharmaceutical industry, including distributors and healthcare providers in the regions where Labiana Health SA has a presence. The company’s R&D and manufacturing capabilities support the production of medicines that meet regulatory standards for global markets. Labiana Health SA’s business model relies on its subsidiaries in Ecuador, Mexico, Serbia, and Turkey to facilitate market access and distribution. The company’s revenue streams are derived from the sale of pharmaceutical products, regulatory services, and the development of new drug formulations. Its focus on sterile and lyophilized dosage forms positions it within the specialized pharmaceutical manufacturing sector, targeting both animal and human medicine segments. Labiana Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labiana Health stock

Net Debt to Equity Ratio of Labiana Health is 5.86 in 2025.

Net Debt to Equity Ratio of Labiana Health changed from 9.37 to 5.86, representing a -37.44% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Equity Ratio Labiana Health since 2006 – with annual values, charts, and detailed analysis.

Net Debt/Equity adjusts the debt-to-equity ratio by subtracting cash from total debt. It provides a more accurate picture of actual leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Equity Ratio's Labiana Health with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Labiana Health

All Key Metrics — Labiana Health